Francisco J. Esteva, MD, PhD

Articles by Francisco J. Esteva, MD, PhD

7 experts are featured in this series

In this segment, Dr. Gregory Vidal reviews the phase 3 ASCENT-04 trial evaluating sacituzumab govitecan (SG) plus pembrolizumab versus chemotherapy plus pembrolizumab in previously untreated patients with PD-L1–positive metastatic triple-negative breast cancer (TNBC).

7 experts are featured in this series

In this segment, the expert panel discusses the clinical implications of ASCENT-03, evaluating sacituzumab govitecan (SG) against the findings from TROPION-Breast02, which investigated datopotamab deruxtecan (Dato-DXd) in first-line metastatic triple-negative breast cancer (TNBC).

7 experts are featured in this series

In this segment, Dr. Yuan Yuan reviews the phase 3 ASCENT-03 trial evaluating first-line sacituzumab govitecan (SG) versus investigator’s choice of chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic triple-negative breast cancer (TNBC) who were not candidates for immune checkpoint inhibitors.

7 experts are featured in this series

In this segment, the expert panel discusses the clinical implications of TROPION-Breast02 and the potential role of datopotamab deruxtecan (Dato-DXd) in first-line treatment of metastatic triple-negative breast cancer (TNBC) when immunotherapy is not an option.

7 experts are featured in this series

In this segment, the panel reviews the phase 3 TROPION-Breast02 trial evaluating first-line datopotamab deruxtecan (Dato-DXd) versus investigator’s choice of chemotherapy in patients with locally advanced, inoperable, or metastatic triple-negative breast cancer (TNBC) for whom immunotherapy was not an option.

7 experts are featured in this series

In this introductory segment, Dr. William J. Gradishar of Northwestern University Feinberg School of Medicine welcomes viewers to Cancer Network’s Face-Off and introduces the evolving treatment landscape in metastatic triple-negative breast cancer (TNBC).

The epidermal growth factor (EGF) receptor HER2 is a transmembranereceptor tyrosine kinase that plays a crucial role in the regulationof cell proliferation and survival. The overexpression of HER2correlates strongly with prognosis in breast cancer. The targeted blockadeof HER2 activity with monoclonal antibodies (eg, trastuzumab[Herceptin]) and small-molecule tyrosine kinase inhibitors (eg,lapatinib) results in the inhibition of tumor growth in HER2-positivecancers. Anti-HER2 therapies have also shown efficacy in combinationwith chemotherapy in clinical trials in patients with HER2-positive breast cancer. Their efficacy may, however, be limited bymolecular mechanisms that compensate for HER2 suppression (eg,activity of EGF receptor) or mechanisms of resistance (eg, loss ofPTEN). HER2 continues, however, to be overexpressed by the cancercells, and the continued suppression of HER2 may be required formaximum antitumor effect. It should be noted that in the absence ofdefinitive data from randomized trials showing an absence or presenceof benefit, the use of anti-HER2 agents such as trastuzumab in multiplesequential regimens has become the standard of care. CombiningHER2 blockers with agents that overcome the compensatory or resistancemechanisms may increase the efficacy of anti-HER2 therapies.In addition, anti-HER2 therapies can have synergy with common chemotherapyregimens and remain effective through multiple lines oftherapy. Optimizing the use of therapies that target HER2 signalingwill lead to further advances in the treatment of breast cancer.